Formulation Design and Development of Anti-EGFR-BSA-CYP-SLNs In Situ Gel for Nasal Administration

Main Article Content

Sankha Bhattacharya


Aim: A comprehensive approach was taken in the modern era to develop new distinguished in situ gels, as it has good desirability, sustainability, self-administrative approach and bypassing first pass metabolism. In this context, we developed and designed nasal administrable in situ gel containing anti-epidermal growth factor receptor-body surface area-CYP-solid lipid nanoparticle for glioma treatment. Materials and Methods: After multiple screenings, gellan gum (0.25-0.75%), carbopol 934 (0.20-0.60%), and poloxamer 188 (0.20-0.40%) was taken as developing polymers. Box-Behnken design was used for formulation designing. Almost all the formulation (F1-F17) shown good results. Result and Discussion: The various evaluation parameters for all the formulations such as, viscosity (231 ± 1.22 to 656 ± 1.11 CPs), gelling strength (85 ± 0.9 to 180 ± 0.6 s), pH (5.7 ± 0.06 to 6.2 ± 0.08), gelling temperature (31.34 ± 0.78 to 37.34 ± 0.45°C), gel melting temperature (51.06 ± 0.23 to 55.23 ± 0.65°C), % drug content (94.12 ± 0.4 to 98.87 ± 0.1), spreadability (7.28 ± 0.23 to 10.84 ± 0.45 cm), and mucoadhesive strength (4619.56 ± 0.56 to 6501.86 ± 0.22 dyne/cm2) was been recorded. However, F8 turns out to be an optimized formula as it possess good dissolution profile (86.89% at 12th h), zero order kinetics (R2 = 0.9971), maximum desirability factor (D = 0.9921), minimum permeation (9.23% CDP after 720 min study), and maximum skin deposition (91.76%). Further F8 formulation was undergone for stability studies as per ICH Q1A (R2) guideline for 30 days. Conclusion: The results were satisfactory and signify good stability for F8 after 30 days of formulation development. However, further correlative in vivo studies were warranted for more conclusive outcome.


Download data is not yet available.

Article Details

How to Cite
Bhattacharya, S. (2016). Formulation Design and Development of Anti-EGFR-BSA-CYP-SLNs In Situ Gel for Nasal Administration. Asian Journal of Pharmaceutics (AJP), 10(04).